Levetiracetam Tablet, Film Coated
Product Images NDC 63629-7516

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-7516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)
The given text provides formulas for calculating two medical parameters: estimated creatinine clearance (CrCl) and serum creatinine. The first formula measures the CrCl, which is determined by taking 140 and subtracting the patient's age (in years) before multiplying the result by the patient's weight (in kilograms). For female patients, the final result should be multiplied by 0.85. The second formula calculates serum creatinine using a value of 72 and the patient's serum creatinine level (in mg/dL).*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)
FDA Label Image

Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)

Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)
FDA Label Image

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)
The text describes a figure titled "Responder Rate (>50% Reduction From Baseline) In Study 1", which shows the percentage of responders against placebo and different doses of Levetiracetam (1000 mg/day and 3000 mg/day). It also indicates that the higher dose of 3000 mg/day was statistically significant compared to the placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)
This is a graph showing the responder rate in Study 2 for a period of time. The responder rate is represented as (>50% Reduction From Baseline). The graph compares the effectiveness of a Placebo versus two different doses of Levetiracetam. Levetiracetam at a dose of 1000 mg/day had a responder rate of 20%, while Levetiracetam at a dose of 2000 mg/day had a responder rate of 35%. The text also indicates that the difference between the Levetiracetam doses and the Placebo was statistically significant.*
FDA Label Image

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)
This is a chart showing the Responder Rate, which is the percentage of participants who experienced at least a 50% reduction in symptoms compared to their baseline, in Study 3. The chart compares the placebo group (with 104 participants) to the group taking 3000 mg/day of Levetiracetam (with 180 participants). Levetiracetam was found to be statistically significant compared to the placebo.*
FDA Label Image

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)
The figure 4 shows the Responder Rate in Study 4 with reduction from baseline. The graph includes percentages ranging from 5% to 446%. The study included a Placebo group with N=97 and a Levetiracetam group with N=101. The Levetiracetam group showed a statistically significant result as compared to Placebo.*
FDA Label Image

Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)

Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)
The text is not available for generating a useful description.*
FDA Label Image

Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)

Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)
The figure 6 shows the responder rate of patients suffering from PGTC seizure frequency per week in Study 7. The graph shows the percentage of patients who had at least a 50% reduction from baseline in seizure frequency. The placebo group (N=84) had a responder rate of 45.2%, while the Levetiracetam group had a responder rate of 72.2%, which is statistically significant when compared to placebo.*
FDA Label Image

Image 01

Image 01
FDA Label Image

Label Image (Lbl636297516)

Label Image (Lbl636297516)
This is a comparison between a medication, Keppra 1000mg Tablet made by Zhejiang Huahai Pharma Co Ltd, and an unidentified drug packaged by Bryant Ranck Prepack. The unidentified drug is a pack of 30 tablets with an expiration date of MM/YY and NDC number 6362975161. The manufacturer's address is also provided. The drug should be stored at room temperature, and caution should be taken to keep all drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.